Material supplied under the designation 4-phenyl-4-piperidinol pharma grade is the free-base amino alcohol represented by CAS 40807-61-2, molecular formula C₁₁H₁₅NO, and relative molecular mass 177.25 g/mol. The substance is a white to off-white crystalline solid at ambient temperature and belongs to the piperidin-4-ol class rather than the non-oxygenated 4-phenylpiperidine series. This structural distinction is functionally significant because the tertiary carbinol introduces a hydrogen-bond donor/acceptor center that alters crystalline packing, melting range, moisture interaction, and the choice of salt former for parenteral processing. The pharma grade is manufactured under ICH Q7 GMP for active pharmaceutical ingredients and is released against a certificate of analysis that integrates general chapters from USP <621>, USP <731>, USP <741>, USP <921>, USP <281>, USP <467>, USP <233>, USP <429>, USP <61>, USP <62>, and USP <85> where applicable. No single harmonized monograph for this specific molecule is published in the pharmacopeias consulted; therefore the release specification is a supplier-customer agreement built on general chapter methods. The free base is supplied as a pharma-grade API or pharmaceutical intermediate for use in tablet, capsule, granule, and injectable formulations after appropriate salt formation, particle size adjustment, and process validation. The material is not a finished dosage form and is not intended for direct administration without formulation, stability, and bioavailability assessment.

When 4-Phenyl-4-piperidinol Is Selected Over 4-Phenylpiperidine and Related Piperidinol Intermediates

A C4 hydroxyl substituent separates this compound from the non-oxygenated 4-phenylpiperidine series. The hydroxyl adds 16 g/mol to the molecular mass relative to 4-phenylpiperidine, raises the melting range, and supplies a polar contact for crystalline hydrogen bonding. The phenyl substituent at the same carbon increases lipophilicity relative to 4-piperidinol, which lacks the aromatic ring. The combination of a basic piperidine nitrogen and a hindered tertiary alcohol creates two potential salt-forming or hydrogen-bonding loci, but only the nitrogen is readily protonated under standard pharmaceutical processing conditions. Published quantitative solubility, log P, and pKa data for this specific configuration are limited; a preformulation screen using shake-flask solubility in phosphate-buffered saline at 37 °C and pH 1.2, 4.5, and 6.8 is required before selection of a salt for oral or parenteral use. The free base is generally less water-soluble than the hydrochloride or mesylate salt and is therefore used primarily in solid oral intermediates where dissolution can be controlled by particle size reduction. The salt form is preferred for ready-to-use injectable solutions, provided the counterion does not precipitate with phosphate buffer or interact with elastomer closures. A supplier of the pharma grade free base should certify composition by HPLC retention time and infrared identity, while a technical grade intermediate may not carry the same residual solvent, elemental impurity, and microbial controls.

Solid-state comparison with the hydrochloride salt is operationally relevant. The free base typically presents a crystalline powder with a melting endotherm in the region of 160–164 °C by differential scanning calorimetry at 10 °C/min under nitrogen in a crimped aluminum pan. The hydrochloride salt may melt at a different temperature and may require vacuum drying at lower temperature to avoid decomposition; salt formation also changes hygroscopicity, which should be measured by dynamic vapor sorption from 0% to 90% relative humidity at 25 °C. If the free base is chosen for dry powder or capsule processing, moisture uptake is not assumed to be negligible simply because the material is crystalline. The supplier must report loss on drying and water content separately because surface moisture and bound hydrate water are distinct quality attributes.

What Limits Ready-to-Use Administration in Tablet, Capsule, Granule, and Injection Formats?

Direct compression of the free base into tablets is processable when the incoming particle size distribution is controlled. At low drug load, content uniformity failures have been observed in production-scale rotary presses when the D₉₀ exceeds 100 µm and the blend is discharged from a bin with a mass flow pattern. The risk is addressed by sieving through a 500 µm screen, blending with colloidal silicon dioxide at 0.25–0.50% w/w, and monitoring blend uniformity by near-infrared spectroscopy after each lubrication stage. Tablet hardness and disintegration are formulation-dependent and must be tested under USP <701> and USP <2040>; dissolution is evaluated under USP <711> on the finished tablet. Compression force settings on a rotary tablet press are adjusted to achieve a tensile strength of 1.5–2.5 MPa for non-friable cores; friability is tested per USP <1216>. If the formulation contains lactose monohydrate, amino-reactivity screening is required because the secondary amine can participate in Maillard-type degradation under heat and moisture. For direct compression, the API particle size should be laser-diffraction controlled under USP <429> or Ph. Eur. 2.9.31; a sieve-only specification is not sufficient to detect fines that cause segregation.

Capsule filling of the free base is influenced by bulk and tapped density, which are determined under USP <616>. If the Carr Index is greater than 30%, flowability is improved by adding 0.5–1.0% w/w fumed silica or by granulating before encapsulation. Tamping-pin machines and dosator machines may produce different fill weights for the same bulk powder because the material has limited free-flowing properties after milling; therefore machine-specific fill weight monitoring by gravimetric checkweigher is required. Hard gelatin capsules and hydroxypropyl methylcellulose capsules are both acceptable for oral administration, but compatibility with the free base at long-term storage should be confirmed at 25 °C/60% RH and 40 °C/75% RH per ICH Q1A(R2).

Granules may be prepared by low-shear or high-shear wet granulation. The binder is chosen from povidone K29/32 or hypromellose E5 at 2–5% w/w solids, and the granulation end point is controlled by impeller torque rather than absolute water volume because the free base has limited aqueous solubility and overwetting leads to densification and prolonged drying. Drying is conducted in a fluid-bed dryer to a loss on drying of ≤ 2.0% w/w before milling through a 1.0 mm oscillating granulator. If roller compaction is selected instead of wet granulation, the ribbon density should be held between 0.8 and 1.3 g/cm³ and the roll force must be justified by sieve analysis after milling. Batch-to-batch variance in granule flow has been controlled by fixing the crystallization solvent and particle size distribution of the incoming API; uncontrolled fines and residual solvent changes are frequent causes of granule hardness deviation.

Injectable use requires salt formation to an aqueous-soluble species. The free base is dissolved or reslurried with one equivalent of hydrochloric acid in a mixture of ethanol and water, filtered through activated carbon, and crystallized as the hydrochloride under controlled cooling. The dried salt is reconstituted in Water for Injection, adjusted to pH 4.5–6.0 with citrate or acetate buffer if stability permits, and filtered through a 0.22 µm PVDF membrane. Terminal sterilization by moist heat is acceptable only if the solution is stable at 121 °C for 15 min; otherwise aseptic filtration is required. Pre-filtration stress testing should include pH shift, nitrogen sparging, and exposure to type I glass and elastomer closures. Precipitation risk at pH values above the piperidine nitrogen pKa range must be assessed because the free base may have low solubility near physiologic pH, and no published compendial stability profile for this specific configuration is available. The final injectable product must meet particulate matter limits under USP <788> or Ph. Eur. 2.9.19, sterility under USP <71>, and bacterial endotoxins under USP <85>.

Specification Verification and Regulatory Release Requirements

Release testing for pharmaceutical application follows general chapters common to APIs rather than a single compendial monograph for this molecule. The certificate of analysis includes lot number, retest date, storage condition below 25 °C in a dry, light-protected container with desiccant, and the methods used for acceptance. Compliance with ICH Q7 is documented through batch records, deviation controls, and change management. Residual solvent testing follows ICH Q3C Option 1 or 2, and elemental impurity risk assessment follows ICH Q3D. For oral solid dosage formulations, compendial tests for dissolution, disintegration, and uniformity of dosage units are executed on the finished product according to USP <711>, USP <701>, and USP <905>. The API itself is not assigned a dissolution specification; dissolution is a formulation property. For injectable formulations, the solution is tested for visible particulates under USP <790> and subvisible particulates under USP <788>, and sterility is established by membrane filtration under USP <71>.

Because the same CAS number can be supplied as a technical-grade intermediate, the following distinction is operationally relevant for oral and injectable pharmaceutical manufacturing.

For oral solid dosage forms, the free base should not be combined with amine-reactive excipients such as reducing sugars under high-shear heat and moisture without compatibility testing, because the secondary amine may undergo Maillard-type degradation. For parenteral processing, avoid combination with uncoated borosilicate glass at high pH and with citric acid buffer if the salt shows reduced solubility through a common-ion effect or pH shift. Processing of micronized material should be conducted in a downflow booth with high-efficiency particulate air filtration to reduce operator exposure, and inerting of mills with nitrogen is recommended because fine organic dust may form a combustible atmosphere. Published data for this specific configuration is limited; therefore forced degradation at 40 °C/75% RH, 50 °C dry, acid/base hydrolysis, and oxidative stress should be generated before final specification and route-of-administration decisions are made.